This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Christensen, J. G. Articles by Mendel, D. B. Search for Related Content PubMed PubMed Citation Articles by Christensen, J. G. Articles by Mendel, D. B.

A Selective Small Molecule Inhibitor of c-Met Kinase Inhibits c-Met-Dependent Phenotypes in Vitro and Exhibits Cytoreductive Antitumor Activity in Vivo

Preclinical Research and Exploratory Development [J. G. C., R. S., J. B., P. K., E. C., J. M. C., D. B. M.], Discovery Technology and Biology [P. L., J. C., X. W., L. R., R. B., K. E. L.], and Chemistry [J. R., S. D., J. J. C.], SUGEN, Inc., South San Francisco, California 94080

	ABSTRACT

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS Cell Assays In Vivo Studies Target Modulation Studies Efficacy Studies RESULTS DISCUSSION REFERENCES

 
The c-Met receptor tyrosine kinase and its ligand, hepatocyte growth factor (HGF), have been implicated in the development and progression of several human cancers and are attractive targets for cancer therapy. PHA-665752 was identified as a small molecule, ATP-competitive, active-site inhibitor of the catalytic activity of c-Met kinase (K_i 4 nM). PHA-665752 also exhibited >50-fold selectivity for c-Met compared with a panel of diverse tyrosine and serine-threonine kinases. In cellular studies, PHA-665752 potently inhibited HGF-stimulated and constitutive c-Met phosphorylation, as well as HGF and c-Met-driven phenotypes such as cell growth (proliferation and survival), cell motility, invasion, and/or morphology of a variety of tumor cells. In addition, PHA-665752 inhibited HGF-stimulated or constitutive phosphorylation of mediators of downstream signal transduction of c-Met, including Gab-1, extracellular regulated kinase, Akt, signal transducer and activator of transcription 3, phospholipase C , and focal adhesion kinase, in multiple tumor cell lines in a pattern correlating to the phenotypic response of a given tumor cell. In in vivo studies, a single dose of PHA-665752 inhibited c-Met phosphorylation in tumor xenografts for up to 12 h. Inhibition of c-Met phosphorylation was associated with dose-dependent tumor growth inhibition/growth delay over a repeated administration schedule at well-tolerated doses. Interestingly, potent cytoreductive activity was demonstrated in a gastric carcinoma xenograft model. Collectively, these results demonstrate the feasibility of selectively targeting c-Met with ATP-competitive small-molecules and suggest the therapeutic potential of targeting c-Met in human cancers.

	INTRODUCTION

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS Cell Assays In Vivo Studies Target Modulation Studies Efficacy Studies RESULTS DISCUSSION REFERENCES

 
RTKs² regulate many key processes in mammalian development, cell function, and tissue homeostasis. These diverse processes include cell growth and survival, organ morphogenesis, neovascularization, and tissue repair and regeneration, among others. Dysregulation of RTKs by mutation, gene rearrangement, gene amplification, and overexpression of both receptor and ligand have been implicated as causative factors in the development and progression of numerous human cancers. The validity of RTKs as therapeutic targets is illustrated by the successes of Gleevec targeting bcr-abl in chronic myelogenous leukemia and c-Kit in gastrointestinal stromal tumors, Herceptin in HER-2 overexpressing breast cancers, and Iressa in select non-small cell lung cancers (1) .

The c-Met RTK is the only known high-affinity receptor for HGF, also known as scatter factor (2 , 3) . Binding of HGF to the c-Met extracellular ligand-binding domain results in receptor multimerization and phosphorylation of multiple tyrosine residues at the intracellular region. Tyrosine phosphorylation at the c-Met juxtamembrane, catalytic, and cytoplasmic tail domains regulates the internalization, catalytic activity, and docking of regulatory substrates, respectively (4, 5, 6, 7) . Activation of c-Met results in the binding and phosphorylation of adaptor proteins such as Gab-1, Grb2, Shc, and c-Cbl, and subsequent activation of signal transducers such as PI3K, PLC-, STATs, ERK 1 and 2, and FAK (8) .

c-Met and HGF are expressed in numerous tissues, and their expression is normally confined predominantly to cells of epithelial and mesenchymal origin, respectively (9 , 10) . The transduction of signaling and subsequent biological effects of HGF by c-Met has been shown to be important in epithelial-mesenchymal interaction and regulation of cell migration, invasion, cell proliferation and survival, angiogenesis, morphogenic differentiation, and organization of 3-dimensional tubular structures (e.g., renal tubular cells, gland formation, and so forth; Refs. 11 , 12 ). In addition, c-Met and HGF are each required for normal mammalian development, and they are believed to be important in regulating epithelial-mesenchymal transitions during organ morphogenesis (13, 14, 15) .

c-Met and HGF are dysregulated in human cancers and are also believed to contribute to dysregulation of cell growth, tumor cell dissemination, and tumor invasion during disease progression and metastasis. This suggests that c-Met and HGF may be attractive candidates for targeted cancer therapy. c-Met and HGF are highly expressed relative to surrounding tissue in numerous cancers, and their expression correlates with poor patient prognosis (12) . c-Met activating point mutations in the kinase domain are implicated as the cause of hereditary papillary renal carcinoma (16) . In addition, kinase domain mutations have been observed in sporadic papillary renal carcinoma, ovarian cancer, childhood hepatocellular carcinoma, and gastric cancer (16, 17, 18) . Furthermore, mutations in head and neck squamous cell carcinoma metastases, and mutations and gene amplification in colorectal cancer metastases, implicate c-Met in the metastatic progression of these cancers (19 , 20) . Cell lines engineered to express high levels of c-Met and HGF (autocrine loop) or mutant c-Met displayed a proliferative, motogenic, and/or invasive phenotype, and grew as metastatic tumors in nude mice (21, 22, 23, 24, 25) . In addition, transgenic mice overexpressing c-Met, HGF, or mutant c-Met display a tumorigenic and metastatic phenotype (26 , 27) .

c-Met receptor antagonists including ribozymes, dominant-negative proteins, and HGF kringle-variants such as NK4 have been shown to reverse c-Met/HGF biological phenotypes, and inhibit tumor growth and dissemination (28, 29, 30, 31) . Collectively, these data additionally support the potential for targeting c-Met with small-molecule therapeutics. Recently, K252a, a Staurosporine analogue and inhibitor of multiple protein kinases, demonstrated submicromolar c-Met activity, and modulated wild-type and mutant c-Met-dependent function and dissemination of tumor cells in vivo supporting the concept of development of small molecule c-Met RTK inhibitors (32) .

To address the issue of compound selectivity in characterization of c-Met function, we have identified a series of selective small molecule c-Met RTK inhibitors. A prototype from this small-molecule family, PHA-665752, was shown to potently inhibit c-Met enzyme with a K_i of 4 nM and an IC₅₀ of 9 nM. PHA-665752 was >50x selective over a large panel of other tyrosine and serine-threonine kinases, supporting its utility in selectively characterizing c-Met-dependent signal transduction, function, and mechanism-of-action in vivo. In cells, PHA-665752 also inhibited c-Met phosphorylation and c-Met-dependent motility, invasion, and proliferation with IC₅₀values in the low nanomolar range, and modulated known c-Met signal transducers including ERKs, Akt, and FAK. In mouse tumor models, PHA-665752 inhibited Met phosphorylation and signal transduction, which correlated with tumor growth inhibition or tumor regression at well-tolerated doses. These results support the therapeutic potential of targeting c-Met in cancers where c-Met plays a role in tumor growth or metastasis.

	MATERIALS AND METHODS

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS Cell Assays In Vivo Studies Target Modulation Studies Efficacy Studies RESULTS DISCUSSION REFERENCES

 
Compound.
PHA-665752 (3Z)-5-[(2,6-dichlorobenzyl)sulfonyl]-3-[(3,5-dimethyl-4-{[(2R)-2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl]carbonyl}-1H-pyrrol-2-yl)methylene]-1,3-dihydro-2H-indol-2-one (Fig. 1) was synthesized at SUGEN, Inc.

View larger version (12K): [in this window] [in a new window] [Download PPT slide]   Fig. 1. Structure of PHA-665752.

In Vitro Enzyme Assays.
The IC₅₀ values of PHA-665752 for the inhibition of c-Met and various other kinases were determined as described previously (34) . Briefly, c-Met kinase domain GST-fusion protein was used for the c-Met assay, whereas recombinant human full-length or GST-kinase domain fusion proteins were used in other enzyme assays. IC₅₀ measurements of compound versus kinases were based on phosphorylation of kinase peptide substrates or poly-glu-tyr in the presence of ATP and divalent cation (MgCl₂ MnCl₂ 10–20 mM). The linear range (i.e., the time period over which the rate remained equivalent to the initial rate) was determined for each kinase, and all of the kinetic measurements and IC₅₀ determinations were performed within this range. K_m values were calculated using the Eadie-Hofstee and Lineweaver-Burke methods with the final ATP concentrations within two to three times the K_m value.

	Cell Assays

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS Cell Assays In Vivo Studies Target Modulation Studies Efficacy Studies RESULTS DISCUSSION REFERENCES

 
Cell Proliferation Assays.
S114, GTL-16, NCI-H441, or BxPC-3 cells were seeded in 96-well plates at 9000 cells/well in medium with 10% FBS. After incubation for 48 h in low serum (0.5% FBS, S114; 0.1% FBS, GTL-16, NCI-H441, and BxPC-3), cells were treated with different concentrations of PHA-665752 for 18 h at 37°C. HGF (50 ng/ml) was added for 18 h before BrdUrd for studies involving GTL-16, H441, and BxPC-3. After incubation with BrdUrd labeling reagent for 1 h (Sigma Biochemicals, St. Louis, MO), cells were fixed and BrdUrd incorporation into newly synthesized DNA was assessed using anti-BrdUrd peroxidase-conjugated antibody followed by colorimetric determination at 630 nm.

Scatter Assay.
MDCK cells were seeded at low density (25 cells/well) in a 96-well plate in MEM with 10% FBS and grown until small colonies of 10–15 cells appeared. Cells were then stimulated with HGF/scatter factor (50 ng/ml) in the presence of various concentrations of PHA-665752 diluted in growth medium. After overnight incubation, colonies were fixed and stained with 0.2% crystal violet in 10% buffered formalin and assessed for scattering at each concentration visually and by an image analysis algorithm designed to measure scattering over several experimental replicates (>10).

Migration Assay.
Cells were seeded in RPMI 1640 at 10% FBS, grown until confluent, and a gap was introduced by scraping cells with a P200 pipette tip. Cells were then stimulated to migrate across the gap with HGF (50 ng/ml) in the presence of various concentrations of PHA-665752 diluted in growth medium. After an overnight incubation, a qualitative assessment of inhibition of migration was performed at each concentration.

Three-Dimensional Invasion/Tubulogenesis Assay.
Matrigel (Matrigel Basement Membrane Matrix; Becton Dickinson Labware) was thawed on ice. Matrigel was plated at 50 µl/well in 96-well plate and incubated for 20 min at 37°C to induce gel formation. RIE-1 cells were suspended at 2 x 10⁴ cell/ml and mixed 1:1 with Matrigel on ice. We added 0.1 ml of the mixture per well. After 24 h, 0.1 ml DMEM ± 80 ng/ml HGF (R&D 294-hg-005) ± various concentrations of PHA-665752 were added on top of each Matrigel cell plug. Fresh medium ± HGF was added every 3 days. Photographs were taken after 6 days in culture.

Apoptosis Assay.
Cells were seeded at 54,000 cells/well in 24-well plates in medium containing 2% FBS in presence and absence of HGF (50 ng/ml), and various concentrations of PHA-665752. After 72 h, medium was aspirated and replaced by a mixture containing ethidium bromide (200 nM) and acridine orange (200 nM; both: Sigma Biochemicals, St. Louis, MO) in PBS (pH 7.4). Cells (1000/well) were counted under a microscope at x20 with a fluorescent filter at 520 nm. Apoptotic cells stained brightly orange indicating presence of condensed chromatin and lack of nuclear membrane integrity. Necrotic cells stained a dull orange and were not included in this analysis. Results were expressed as percentage of apoptotic cells (1000 total cells counted).

Soft Agar Assay.
Cells were seeded at 5000 cells/well in a 12-well plate in medium containing FBS (1%), in the presence and absence of HGF (100 ng/ml) and PHA-665752 over a base agar layer (0.5 ml of 1:1 mixture of 20% FBS containing medium and 1.2% agar solution). The plates were incubated (37°C, 5% CO₂), and the number and size of colonies were evaluated under each condition after 7–14 days.

Antibodies.
Rabbit polyclonal antibodies included antihuman-met (sc-161; Santa Cruz Biotechnology Biotech, Santa Cruz, CA); antiphosphorylated-c-Met (pY1230/4/5; Biosource, Camarillo, CA); antiphosphorylated c-Met (pY1003; Biosource); anti-pY (SUGEN); anti-Gab-1 for immunoprecipitation; Santa Cruz Biotechnology, Inc.); anti-Gab-1 for immunoblot (Upstate Biotechnology, Inc., Waltham, MA), antiphosphorylated-p44/42 ERK mitogen-activated protein kinase, (Thr 202/Tyr204; Cell Signaling Technology, Beverly, MA); anti-ERK mitogen-activated protein kinase, (Cell Signaling Technology); anti-phosphorylated-Akt (Ser473, IHC specific; Cell Signaling Technology); antiphosphorylated-Akt (Ser473, immunoblotting; Cell Signaling Technology, Beverly); antiphosphorylated-FAK Y861 (Biosource); anti-STAT-3 (Cell Signaling); antiphosphorylated STAT-3 (Thr705; Cell Signaling); anti-PLC- (Santa Cruz Biotechnology); antiphosphorylated PLC- (Tyr783; Cell Signaling); and mouse monoclonal anti-FAK (BD Biosciences, San Jose, CA).

Immunoblot Analysis.
The expression and phosphorylation of c-Met and its signaling proteins were evaluated by immunoblotting with antibodies listed above. Briefly, protein lysates were made from pelleted cells or powdered frozen tumor tissue as described previously (35) by incubation in lysis buffer with protease and phosphatase inhibitors [50 mM HEPES (pH 7.5), 150 mM NaCl, 1.5 mM magnesium chloride, 10% Glycerol, 1% Triton X-100, 1 mM sodium orthovanadate, 0.5 mM sodium fluoride, aprotinin (2 µg/ml), leupeptin (2 µg/ml), pepstatin A (2 µg/ml), and phenylmethylsulfonyl fluoride (1 mM)] at 4°C. Protein lysates were cleared of cellular debris by centrifugation at 15,000 x g for 15 min, resolved by electrophoresis on 8% SDS-PAGE gels, and electrotransferred to a nitrocellulose membrane. In the experiments involving Gab-1 lysates were immunoprecipitated for the specific protein of interest before electrophoresis and transfer. Proteins were detected using standard immunoblotting procedures using the antibodies listed above.

Immunofluorescence Analysis.
Cells used in immunofluorescence studies (GTL-16, NCI-H441, and MDCK) were grown on coverslips in six-well plates. The designated amounts of HGF and/or PHA-665752 were added to coverslips for each experiment. Briefly, cells were fixed in 100% methanol for 30 min at -20°C and washed four times in TBS (pH 7.4). Fixed cells were then: (a) blocked in 10% FBS in TBS for 60 min; (b) incubated in primary antibody (c-Met, sc-161; 1:1000) in 10% FBS in TBS for 60 min; (c) washed four times in TBS; (d) incubated with an antirabbit fluorescent-tagged secondary antibody (1:4000) in 10% FBS in TBS for 60 min; and (e) washed four times in TBS. Coverslips were then mounted on slides and evaluated by fluorescence microscopy using a Lieca DMLB HC Photomicroscopy system.

	In Vivo Studies

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS Cell Assays In Vivo Studies Target Modulation Studies Efficacy Studies RESULTS DISCUSSION REFERENCES

 
Animals.
Female athymic mice (nu/nu, 8–12 weeks old) were obtained from Charles River Breeding Laboratories (Wilmington, MA). Animals were housed on a 12-h light/dark cycle with food and water provided ad libitum in a barrier facility fully accredited by the Association for Assessment and Accreditation of Laboratory Animal Care, International. Animals were examined before the initiation of experiments to ensure that they were healthy and acclimated to the laboratory environment. All of the procedures were conducted in accordance with the Institute for Laboratory Animal Research Guide for the Care and Use of Laboratory Animals and with SUGEN Animal Care and Use Committee guidelines.

	Target Modulation Studies

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS Cell Assays In Vivo Studies Target Modulation Studies Efficacy Studies RESULTS DISCUSSION REFERENCES

 
Tumor Pharmacodynamics.
In vivo target modulation studies were performed in mice bearing S114 or GTL-16 tumor xenografts to determine the effect of PHA-665752 on c-Met phosphorylation in both single-dose and repeat-dose studies. For all of the target modulation studies, mice bearing established tumors (200–1200 mm³) were administered PHA-665752 or vehicle [L-lactate (pH 4.8) and 10% polyethylene glycol] via bolus i.v. tail vein injection at the desired dose in a volume of 150 µl. At the indicated times after administration, a blood sample was isolated from cardiac left ventricle using a syringe primed with heparin sulfate, mice were euthanized, and their tumors were resected. Resected tumors were immediately frozen and pulverized using a liquid nitrogen-cooled cryomortar and pestle. Tumor powders were processed into lysates by homogenization in cold lysis buffer with protease and phosphatase inhibitors (35) . The amount of phosphorylated and total c-Met in each sample was determined by immunoblot analysis of protein lysates as described above.

	Efficacy Studies

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS Cell Assays In Vivo Studies Target Modulation Studies Efficacy Studies RESULTS DISCUSSION REFERENCES

 
Repeated-Dose Administration Tumor Growth Inhibition.
Efficacy studies were performed in athymic mice bearing S114 or GTL-16 tumor xenografts to determine the effect of PHA-665752 on tumor growth. Tumor cells (5 x 10⁶ cells/animal) were implanted s.c. into the hindflank region of mice on day 0. Daily treatment with inhibitor was initiated when tumors were 50 mm³ or 400 mm³ in size for S114 and GTL-16, respectively. PHA-665752 or vehicle (described above) was administered as daily i.v. bolus via tail vein injection for up to 10 days. Tumors were measured twice weekly using Vernier calipers, and tumor volumes were calculated as the product of length x width x height. At the end of the study, tumor growth inhibition values were expressed as: 1- (mean treated tumor mass/mean control tumor mass *100). For the GTL-16 efficacy study a representative cohort (n = 3) of animals were sacrificed at the times indicated, their tumors resected, and a blood sample taken from the cardiac left ventricle using a syringe primed with heparin sulfate. Resected tumors were cut in half. One half was fixed in 10% neutral buffered formalin, paraffin embedded, and sectioned for immunohistochemistry, and the other half immediately frozen and subsequently processed into tumor powder, and ultimately protein lysates, for Western blot analysis as described above.

Immmunohistochemical Studies.
Resected mouse xenografts were fixed in 10% neutral buffered formalin (Protocol; Fisher Scientific, Pittsburgh, PA) with protease inhibitor (0.5 mM sodium fluoride) and phosphatase inhibitor (1 mM sodium orthovanadate). Tissue was fixed overnight and stored in 70% ethanol until embedded in paraffin. Four µm sections were cut and baked on Superfrost plus microscope slides (Fisher Scientific). The Ventana Benchmark automated staining system (Ventana Medical Systems, Tucson, AZ) was used according to manufacturers instructions for deparaffinization, antigen retrieval [citrate buffer (pH 7.4) at 94°C for 30 min] and immunohistochemical staining. H&E stains were performed for each section to gain orientation. Primary rabbit polyclonal antibodies used for immunohistochemical studies (c-Met, phosphorylated c-Met, and phospho-ERK, Akt, and FAK antibodies) are described above. The secondary antibody in each case was biotinylated goat antirabbit IgG (Vector). Stained sections were analyzed and documented using a Lieca DMLB HC Photomicroscopy system.

	RESULTS

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS Cell Assays In Vivo Studies Target Modulation Studies Efficacy Studies RESULTS DISCUSSION REFERENCES

 
Identification of PHA-665752 as a Potent and Selective Inhibitor of c-Met Activity and Function.
Putative c-Met inhibitors were identified using biochemical assays with isolated GST-Met kinase domain and HGF-dependent cellular kinase, proliferation, and motility assays. In biochemical assays, PHA-665752 (structure in Fig. 1 ) demonstrated potent, ATP-competitive inhibition of c-Met kinase activity with an K_i of 4 nM and IC₅₀ of 9 nM. In addition to the potent biochemical activity against c-Met enzyme, PHA-665752 also demonstrated potent inhibition of c-Met RTK autophosphorylation in NIH3T3 cells engineered to express high levels of c-Met and HGF (S114 cells), HGF-stimulated A549 lung carcinoma cells, and mouse B16-F1 melanoma cells (Table 1 ; Fig. 2A ).

View larger version (93K): [in this window] [in a new window] [Download PPT slide]   Fig. 2. Effects of PHA-665752 on (A) HGF-induced c-Met phosphorylation in A549 cells, (B) HGF-induced motility in MDCK cells, (C) HGF-induced migration in NCI-H441 cells, (D) morphology of GTL-16 cells, and (E) invasion/tubulogenesis of RIE cells. A, A549 cells were exposed to the indicated concentrations of PHA-665752 for 4 h. Cells were then stimulated with HGF (50 ng/ml), denoted by (+) for 10 min. c-Met protein expression and phosphorylation state were determined after immunoprecipitation of the receptor from tumor lysate and subsequent immunoblot analysis as described in "Materials and Methods." B, MDCK cells were grown as small colonies at low density and treated with HGF (50 ng/ml) in the presence of various concentrations of PHA-665752. After an overnight incubation, cells in absence or presence of HGF or PHA-665752 (0.1 µM) were visualized via c-Met immunofluorescence staining and microscopy. C, NCI-H441 cells were grown to high density and a gap was introduced with a P200 pipette tip. Cells were then stimulated to migrate across the gap with HGF (50 ng/ml) in the presence of various concentrations of PHA-665752. After an overnight incubation, cells in absence or presence of HGF or PHA-665752 (0.1 µM) were visualized via c-Met immunofluorescence staining and microscopy. D, GTL-16 cells were cultured overnight in the presence and absence of HGF (50 ng/ml) and PHA-665752 (0.1 µM), visualized by light microscopy, and photographed. E, RIE cells were added to Matrigel and grew as small plugs. After 24 h, cells were stimulated with HGF (80 ng/ml) to invade and form tube-like structures in Matrigel in the presence or absence of various concentrations of PHA-665752.

Characterization of the Effect of PHA-665752 on Signal Transduction in Tumor Cells and Correlation with c-Met-Dependent Function.
PHA-665752 was also evaluated for its effect on phosphorylation of proteins known to transduce c-Met-dependent signals in cell lines that exhibit c-Met-dependent functional properties. In each of these cell lines, PHA-665752 was evaluated for its effect on constitutive or HGF-stimulated cell morphology, cell growth, and motogenic properties in monolayer as well as anchorage-independent growth in soft agar (summarized in Table 3 ). This analysis of c-Met-dependent signal transduction and functional response is focused on concentrations of PHA-665752 (0.1 µM in monolayer, 0.2 µM in agarose) that demonstrated: (a) complete inhibition of c-Met phosphorylation (in monolayer and colonies in agarose); and (b) selectivity for c-Met versus other kinases evaluated. PHA-665752 did not demonstrate an effect on cell growth or viability in c-Met-negative control cells at 10-fold above the concentrations at which the analyses were performed (data not shown). [Negative control cells included cells in which inhibition of c-Met is predicted to have minimal consequences (e.g., NIH3T3-VEGFR2, rat-1-N-myc fibroblasts, and SK-BR-3 breast)].

View larger version (27K): [in this window] [in a new window] [Download PPT slide]   Fig. 3. Effect of PHA-665752 on cell proliferation (A), cell survival (B), and growth in soft agarose (C) in GTL-16, NCI-H441, and/or BxPC-3 cells. A, for proliferation assays, adherent cells were grown in medium with 0.1% FBS for 48 h after which they are treated with various concentrations of PHA-665752 in HGF (50 ng/ml) in medium containing 2% FBS. After 18 h, cells were incubated with BrdUrd for 1 h, fixed, and stained with anti-BrdUrd peroxidase-conjugated antibody, and plates were read at 630 nm. Columns in graphs represent mean absorbance (total BrdUrd incorporation/well) for each condition over three independent experiments; bars, ±SD. B, for apoptosis assays, adherent cells were grown in medium with 2% FBS, in presence and absence of HGF (50 ng/ml) and various concentrations of PHA-665752. After 72 h, a mixture containing ethidium bromide and acridine orange was added, and apoptotic cells (bright orange cells or cell fragments) were counted by fluorescence microscopy. Columns in graph represent mean % apoptotic cells (1000 total cells counted) for each condition over three independent experiments; bars, ±SD. C, for soft agarose colony forming assays, cells were seeded in medium containing 1% FBS in presence and absence of HGF (100 ng/ml) and PHA-665752 (0.25 or 0.5 µM) over a base agar layer. Concentrations of PHA-665752 for soft agarose experiments were determined by inhibition of c-Met phosphorylation in colonies in soft agarose (IC50: 0.2 µM). Plates were incubated for 7–14 days, and the number of colonies was evaluated under each condition. Columns in graph represent mean number of colonies for each condition over two independent experiments; bars, ±SD.

View larger version (65K): [in this window] [in a new window] [Download PPT slide]   Fig. 4. Effect of PHA-665752 on c-Met phosphorylation and signal transduction in GTL-16, NCI-H441, and BxPC-3 cells. Cells were treated with PHA-665752 (0.1 µM) for 3 h and with HGF (50 ng/ml) for 10 or 30 min. Lysates were made for cells under each condition, and immunoblotting was performed for each protein or phosphoprotein of interest using specific antibodies as described in "Materials and Methods." Total Gab-1 was immunoprecipitated from protein lysates before immunoblotting. Representative blots from two independent experiments are shown in Fig. 4.

Similarly, in H441 cells, in which c-Met demonstrated a role in cell growth and motility, PHA-665752 potently inhibited constitutive signaling through the ERK, Akt, and FAK pathways, and partially inhibited PLC- phosphorylation (Fig. 4) . Similar to observations in GTL-16 cells, signaling molecules appeared to exhibit constitutive activity; however, addition of HGF did appear to additionally stimulate FAK phosphorylation (Fig. 4) . The ability of HGF to additionally induce c-Src-dependent FAK phosphorylation and cell motility in NCI-H441 is consistent with reports that this pathway is necessary for motility (38 , 39) . In addition, the down-regulation of ERK, Akt, and FAK pathways by PHA-665752 is consistent with regulation of both cell growth and motility by c-Met in H441 cells. In contrast to GTL-16 and H441 cells, the only signaling molecules that were markedly modulated by HGF or PHA-665752 in BxPC-3 cells were ERKs 1 and 2, which is consistent with the mild mitogenic response to HGF and inhibition by PHA-665752 (Fig. 4) .

Inhibition of c-Met Phosphorylation in Tumor Xenografts in Vivo by PHA-665752 and Antitumor Efficacy in c-Met-Dependent Tumor Models.
After demonstration of the inhibition of c-Met-dependent phosphorylation and cellular response to PHA-665752 in vitro, experiments were performed to evaluate its in vivo activity. S114 and GTL-16 models (s.c. tumor xenografts implanted in the hindflank of athymic mice) were selected for in vivo pharmacodynamic and efficacy studies because of the dependence on c-Met for cell growth in vitro and demonstration of constitutive phosphorylation of c-Met in tumors in vivo.

An initial study was designed to demonstrate pharmacodynamic inhibition of c-Met phosphorylation by PHA-665752 in tumors in vivo, and to determine the extent and duration of inhibition of c-Met phosphorylation after a single i.v. bolus dose of compound. As shown in Fig. 5A , after a single i.v. dose of PHA-665752 at 25 mg/kg to mice bearing S114 tumor xenografts (approximately 300–400 mm³), c-Met phosphorylation (pY1230/34/35) in S114 tumors was potently inhibited through 12 h and returned to basal levels by 18 h. Similar patterns were observed in subsequent studies.

View larger version (46K): [in this window] [in a new window] [Download PPT slide]   Fig. 5. Inhibition of c-Met phosphorylation (A and C) and tumor growth (B) in the S114 tumor xenograft model. A, athymic mice bearing S114 tumors (300–400 mm3) were given a single i.v. dose (25 mg/kg) of PHA-665752 or vehicle. At several time points after administration, mice were euthanized, plasma and tumor samples were collected, and lysates were prepared as described in "Materials and Methods." The relative abundance of phospho-c-Met [pY1230/34/35] and total c-Met in the tumor lysates was determined by immunoblot analysis. Additional experiments in S114 tumors with PHA-665752 exhibited similar results. B, athymic mice bearing established (50 mm3) S114 tumors were administered daily i.v. doses of PHA-665752 (7.5, 15, 30 mg/kg/day) or vehicle starting on day 7 through day 16. At least 10 mice were included in each group. Results shown indicate mean tumor volume; bars, ±SE. C, on day 16 of the efficacy study in 6B, at 4 h after final administration of PHA-665752, mice bearing S114 tumors (3/group) were euthanized, plasma and tumor samples were collected, and lysates were prepared for analysis of phospho-c-Met (pY1230/34/35) and total c-Met by immunoblot analysis at each dose.

Studies designed to investigate effects of PHA-665752 on pharmacodynamic and tumor growth response in the nonengineered GTL-16 model were also conducted. Interestingly, repeat-dose i.v. administration of PHA-665752 at 25 mg/kg resulted in significant reduction in mass of large, established (450 mm³) GTL-16 tumors, whereas the mass of vehicle-treated tumors continued to increase over the 9-day treatment schedule (Fig. 6A) . A marked reduction in tumor volume was observed as early as 4 days after repeat-dose administration and was >40% smaller than the starting tumor mass by the end of the study. As shown in Fig. 6B , the antitumor effect of PHA-665752 was consistent with complete pharmacodynamic inhibition of c-Met phosphorylation at 4 h after dose as early as day 1 of the study. Similar to S114 studies, evaluation of PHA-665752 in subsequent experiments in the GTL-16 model demonstrated sustained inhibition of c-Met phosphorylation through 12 h after a single dose. In contrast to the S114 model, repeat-dose i.v. administration of 30, 15, and 7.5 mg/kg/day each demonstrated a similar potent antitumor effect with minimal evidence of dose-response in an independent GTL-16 study over 14 days (data not shown). These are the first studies demonstrating cytoreductive activity or tumor growth inhibition by a selective small molecule c-Met inhibitor.

View larger version (34K): [in this window] [in a new window] [Download PPT slide]   Fig. 6. Evidence of cytoreductive activity (A) and inhibition of c-Met phosphorylation (B) in the GTL-16 gastric tumor xenograft model. A, athymic mice bearing large established (400 mm3) GTL-16 tumors were administered a daily i.v. dose of PHA-665752 (25 mg/kg/day) or vehicle starting on day 20 through day 28. At least 10 mice were included in each group. Results shown indicate mean tumor volume; bars, ±SE. B, on day 28, at 4 h after final administration of PHA-665752, mice bearing GTL-16 tumors (3/group) were euthanized, tumor samples were collected, frozen, and pooled, and lysates were prepared for analysis of phospho-c-Met (pY1230/34/35) and total c-Met by immunoblot analysis.

View larger version (67K): [in this window] [in a new window] [Download PPT slide]   Fig. 7. Immmunohistochemical evaluation of c-Met phosphorylation, signal transduction, and tumor pathobiology in GTL-16 xenografts after treatment with PHA-665752. Tumor samples were collected from satellite groups from the GTL-16 study in Fig. 7 at 4 h after dose on days 1, 2, 4, and 8, fixed in neutral-buffered formalin for 24 h and placed in 70% ethanol. Fixed tumors were embedded in paraffin, cut into 4 mm sections, and baked on slides, and evaluated stained with H&E or evaluated for presence of each marker of interest as described in "Materials and Methods." Slides from PHA-665752 and vehicle-treated groups were visually assessed for expression and distribution of proteins of interest by light microscopy.

	DISCUSSION

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS Cell Assays In Vivo Studies Target Modulation Studies Efficacy Studies RESULTS DISCUSSION REFERENCES

 
The validity of therapeutic approaches to target RTKs that are dysregulated in human cancers are illustrated by the successes of Gleevec targeting bcr-abl in chronic myelogenous leukemia and c-Kit in gastrointestinal stromal tumors, Herceptin in HER-2 overexpressing breast cancers, and Iressa in select non-small cell lung cancers (1) . The c-Met RTK has similar compelling evidence supporting its role in cancer and, hence, development of therapies that inhibit c-Met function. This supporting evidence includes: (a) the mutation, gene amplification, or overexpression of c-Met in a variety of cancers; (b) tumorigenic and metastatic properties of cell lines engineered to express c-Met and HGF; (c) development of tumors of multiple origins in c-Met and HGF transgenic animals; and (d) the inhibition of tumorigenic and metastatic properties of tumor cells using a variety of antagonists of c-Met function such as c-Met ribozymes, antisense, dominant-negative receptors, and NK4 (40) . Here, we demonstrated that a selective small-molecule inhibitor targeting the catalytic activity of c-Met inhibits the oncogenic (proliferation, apoptosis, and anchorage-independent growth), prometastatic properties (motility and invasion), and signaling of c-Met in vitro, and pharmacodynamic inhibition of c-Met and antitumor efficacy, including tumor regression, in vivo.

Consistent with the reported pleiotropic effects of HGF and signaling through c-Met, PHA-665752 exhibited cell-type-dependent effects on multiple cellular functional endpoints. In the present studies, PHA-665752 exhibited inhibitory effects on cell growth and/or proliferation to varying degrees on GTL-16, NCI-H441, and BxPC-3 cells. However, differential effects of HGF or PHA-665752 on cell migration (only NCI-H441), cell morphology (only GTL-16 cells), and cell survival (only GTL-16 cells) were observed (summary in Table 3 ). Additional cell lines were identified in which PHA-665752 did not inhibit cell growth endpoints, but did affect an HGF-dependent motogenic response (e.g., AsPC-1 pancreatic and A549 non-small cell lung; data not shown). The regulation of different functions in different cancer cell types by c-Met is consistent with the cell-type and time-dependent coordinated regulation of cell migration, growth, and survival during organ morphogenesis in mammalian development (13 , 15 , 41, 42, 43) . These observations indicate that the role of c-Met in progression of cancers may differ depending on the genetic context or lineage of a given tumor cell, which will be an important consideration in clinical development of c-Met-targeted therapies.

The roles of docking proteins and signaling mediators in regulation of diverse c-Met-dependent cell functions have been elucidated in studies using genetic, biological, and pharmacological means of selective modulation of these pathways. In the present studies, we evaluated the correlation of modulation of c-Met function to modulation of signal transduction molecules in each cell line with a distinct response. In each of the cell lines evaluated in these studies, PHA-665752 inhibited c-Met tyrosine phosphorylation at the activation loop (pY1230/34/35), multifunctional docking site (pY1349), and the juxtamembrane domain (pY1003) at 0.1 µM. Consistent with the inhibition of c-Met phosphorylation at the multifunctional docking site, total tyrosine phosphorylation of Gab-1, the c-Met adaptor protein that binds at this site, was completely inhibited in all of the cell lines evaluated. The consistent modulation of Gab-1 tyrosine phosphorylation by PHA-665752 in these cell line, and others not reported here is consistent with the reported requirement for Gab-1 in the mediation of critical c-Met-dependent cellular functions and the relative specificity for c-Met compared with other RTKs for sustained activation of Gab-1 (43) .

Because downstream signal transducers evaluated in these studies are also activated by other RTKs, as expected, signaling mediators further downstream of c-Met were regulated in a cell-specific manner. One common effect observed was the inhibition of constitutive or HGF-stimulated ERK phosphorylation in each cell line evaluated. The activation of ERKs through the Grb2-SOS-Ras cascade has been linked with uncontrolled cell proliferation, consistent with the regulation of cell growth in each of the cell lines evaluated. Studies with the ERK pathway inhibitor PD98059 have also indicated that sustained activation of this pathway is required but not sufficient for HGF-dependent motogenesis and morphogenesis (44, 45, 46) . Inhibition of constitutive Akt phosphorylation was observed in GTL-16 and H441 cells treated with PHA-665752, indicating the modulation of the PI3K pathway. Studies with inhibitors such as wortmannin and LY294002 have indicated that the PI3K pathway is both required and sufficient for HGF-dependent branching morphogenesis under certain conditions, and is required for motility and cell survival (44 , 47, 48, 49) . These findings support the role of the inhibition of the PI3K pathway by PHA-665752 in regulation of morphogenic differentiation and survival of GTL-16 cells, motility of H441 cells, and lack of these responses in BxPC-3 cells. However, Akt inhibition is observed in both GTL-16 cells and H441 cells with potentially different consequences on cell response. The cell context under which c-Met differentially regulates survival, morphogenesis, and motogenesis through PI3K is not completely understood; however, durability of signaling pathway activation and signaling cross-talk with the ERK pathway have been described as mediators of differential response (44 , 47 , 49 , 50) .

FAK and c-Src are described as being required for loss of intracellular junctions and gain of cell-matrix adhesion during HGF-dependent motility and scatter responses (38 , 39) . In the present studies, phosphorylation of the c-Src-dependent regulatory site of FAK (pY-861) was the only phospho-protein markedly induced by HGF in NCI-H441 cells, whereas other phospho-proteins that were modulated were constitutively activated. Although PHA-665752 inhibited FAK phosphorylation in both GTL-16 and NCI-H441 cells, a motility response to HGF was only observed in NCI-H441 cells. This suggests the possibility that the induction of FAK activity is a rate-limiting step in the motogenic process in these cells. In addition, inhibition of constitutive FAK activity by PHA-665752 in GTL-16 cells suggests a role in morphological change and gain of cell-cell contact observed. The inhibition of STAT-3 and PLC- phosphorylation only in GTL-16 cells is also consistent with the requirement for these proteins in branching morphogenesis and morphological change (41 , 51) . Collectively, the differential regulation of signaling mediators by PHA-665752 in a cell-specific manner is consistent with the differential regulation of cellular functions by c-Met. The understanding of the relationship of regulation of signal transduction to cell function has the potential to facilitate the interpretation of the functional role of c-Met in monitoring the response of a given tumor type to c-Met targeted therapies.

After demonstrating that inhibition of c-Met phosphorylation by PHA-665752 resulted in tumor growth inhibition in the c-Met/HGF engineered S114 model, antitumor and antimetastatic activity was demonstrated in other models. The present studies demonstrating in vivo pharmacodynamics and antitumor efficacy by PHA-665752 begin to demonstrate a correlation between the extent of inhibition of c-Met phosphorylation and inhibition of tumor growth. In addition, the demonstration of inhibition of c-Met in mouse cells and the fact that the animal remained healthy during treatment suggests that an adequate therapeutic index may be possible with a selective inhibitor. Together, these results support the utility of measuring c-Met phosphorylation as a pharmacodynamic marker in the monitoring of antitumor efficacy and safety.

Interestingly, inhibition of c-Met activity by PHA-665752 resulted in cytoreductive activity in the GTL-16 tumor model. GTL-16 contains an amplified c-Met gene locus resulting in expression of high levels of constitutively active c-Met. These data suggest that c-Met may potentially play a role as a survival factor in selected tumors. These tumor types may include those where the receptor is altered by events that result in high constitutive activity, such as gene amplification or mutations, consistent with the precedent set by Gleevec and Herceptin. PHA-665752 inhibited proliferation and induced apoptosis in cultured GTL-16 cells, supporting its role as a survival factor in these cells. In addition, PHA-665752 inhibited ERK, Akt, and FAK phosphorylation in both cultured GTL-16 cells and tumors, suggesting similar alterations in signaling pathways that regulate tumor cell growth and survival both in vitro and in vivo. The evaluation of tumor H&E sections indicated treated tumors exhibited comparatively marked necrotic regions on the interior of the tumor, indicating that extensive cell death occurred in this region of the tumor during PHA-665752 treatment. Collectively, these data support the role of c-Met as a survival factor in selected tumors. Studies to further evaluate c-Met inhibitors in additional models of tumor growth and metastasis, and the correlation of the extent and duration of inhibition of c-Met phosphorylation to antitumor efficacy are warranted and ongoing.

In summary, these studies illustrate the effects of a selective c-Met inhibitor, PHA-665752, as an inhibitor of a variety of c-Met-dependent functions and signaling events. These studies are the first demonstration of inhibition of c-Met phosphorylation and antitumor efficacy, including cytoreductive activity, by a selective, small-molecule c-Met inhibitor. The diversity of response to PHA-665752 in a variety of cell lines indicates the variety of roles that c-Met plays in different cells and, putatively, tumor types. These results suggest that the role of c-Met in tumorigenesis and progression of cancers may differ depending on the genetic context of a given tumor cell. In addition, the understanding of the relationship of regulation of signal transduction to cell function has the potential to facilitate the interpretation of the functional role of c-Met in monitoring the response of a given tumor type to c-Met targeted therapies. The diverse role of c-Met in different tumor types, as a regulator of tumor growth, survival, or metastasis, will be a critical issue in the clinical development of c-Met inhibitors, monitoring of patient response, and design of clinical studies.

	ACKNOWLEDGMENTS

 
We thank the screening groups at Pharmacia Nerviano, Italy and Chesterfield, MO for providing kinase selectivity screening data for PHA-665752. We thank Dr. George VandeWoude and Van Andel Institute, Grand Rapids, Michigan, USA for supplying S114 cells. We also thank Dr. Paolo Comoglio and University Torino Medical School, Torino, Italy for the original supply of GTL-16 cells.

	FOOTNOTES

 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ To whom requests for reprints should be addressed, at Research Pharmacology, Pfizer Global Research and Development, 10724 Science Center Drive, San Diego, CA 92121, Phone: (858) 638-6336; Fax: (858) 526-4120; E-mail: james.christensen{at}pfizer.com

² The abbreviations used are: RTK, receptor tyrosine kinase; HGF, hepatocyte growth factor; ERK, extracellular regulated kinase; STAT, signal transducer and activator of transcription; PLC, phospholipase C; FAK, focal adhesion kinase; PI3K, phosphatidylinositol 3'-kinase; FBS, fetal bovine serum; MDCK, Madin-Darby canine kidney cell; GST, glutathione S-transferase; pY, phosphotyrosine; TBS, Tris-buffered saline; VEGFR, vascular endothelial growth factor receptor; BrdUrd, bromodeoxyuridine; RIE, rat intestinal epithelial.

Received 4/15/03. Accepted 8/26/03.

	REFERENCES

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS Cell Assays In Vivo Studies Target Modulation Studies Efficacy Studies RESULTS DISCUSSION REFERENCES

 

1. Laird A. D., Cherrington J. M. Small molecule tyrosine kinase inhibitors: clinical development of anticancer agents. Expert Opin. Investig. Drugs, 21: 51-64, 2003.
2. Naldini L., Vigna E., Narsimhan R. P., Gaudino G., Zarnegar R., Michalopoulos G. K., Comoglio P. M. Hepatocyte growth factor (HGF) stimulates the tyrosine kinase activity of the receptor encoded by the proto-oncogene c-MET. Oncogene, 6: 501-504, 1991.[Medline]
3. Bottaro D. P., Rubin J. S., Faletto D. L., Chan A. M., Kmiecik T. E., Vande Woude G. F., Aaronson S. A. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science (Wash. DC), 251: 802-804, 1991.[Abstract/Free Full Text]
4. Naldini L., Weidner K. M., Vigna E., Gaudino G., Bardelli A., Ponzetto C., Narsimhan R. P., Hartmann G., Zarnegar R., Michalopoulos G. K. Scatter factor and hepatocyte growth factor are indistinguishable ligands for MET receptor. EMBO J., 10: 2867-2878, 1991.[Medline]
5. Rodrigues G. A., Park M. Autophosphorylation modulates the kinase activity and oncogenic potential of the Met receptor tyrosine kinase. Oncogene, 9: 2019-2027, 1994.[Medline]
6. Ponzetto C., Bardelli A., Zhen Z., Maina F., dalla Zonca P., Giordano S., Graziani A., Panayotou G., Comoglio P. M. A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell, 77: 261-271, 1994.[Medline]
7. Fournier T. M., Lamorte L., Maroun C. R., Lupher M., Band H., Langdon W., Park M. Cbl-transforming variants trigger a cascade of molecular alterations that lead to epithelial mesenchymal conversion. Mol. Biol. Cell, 11: 3397-3410, 2000.[Abstract/Free Full Text]
8. Furge K. A., Zhang Y. W., Vande Woude G. F. Met receptor tyrosine kinase: enhanced signaling through adapter proteins. Oncogene, 19: 5582-5589, 2000.[Medline]
9. Di Renzo M. F., Narsimhan R. P., Olivero M., Bretti S., Giordano S., Medico E., Gaglia P., Zara P., Comoglio P. M. Expression of the Met/HGF receptor in normal and neoplastic human tissues. Oncogene, 6: 1997-2003, 1991.[Medline]
10. Sonnenberg E., Weidner K. M., Birchmeier C. Expression of the met-receptor and its ligand, HGF-SF during mouse embryogenesis. Exs, 65: 381-394, 1993.[Medline]
11. Comoglio P. M., Boccaccio C. Scatter factors and invasive growth. Semin. Cancer Biol., 11: 153-165, 2001.[Medline]
12. Jiang W., Hiscox S., Matsumoto K., Nakamura T. Hepatocyte growth factor/scatter factor, its molecular, cellular and clinical implications in cancer. Crit. Rev. Oncol.-Hematol., 29: 209-248, 1999.[Medline]
13. Bladt F., Riethmacher D., Isenmann S., Aguzzi A., Birchmeier C. Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud. Nature (Lond.), 376: 768-771, 1995.[Medline]
14. Schmidt C., Bladt F., Goedecke S., Brinkmann V., Zschiesche W., Sharpe M., Gherardi E., Birchmeier C. Scatter factor/hepatocyte growth factor is essential for liver development. Nature (Lond.), 373: 699-702, 1995.[Medline]
15. Tsarfaty I., Rong S., Resau J. H., Rulong S., da Silva P. P., Vande Woude G. F. The Met proto-oncogene mesenchymal to epithelial cell conversion. Science (Wash. DC), 263: 98-101, 1994.[Abstract/Free Full Text]
16. Schmidt L., Duh F. M., Chen F., Kishida T., Glenn G., Choyke P., Scherer S. W., Zhuang Z., Lubensky I., Dean M., Allikmets R., Chidambaram A., Bergerheim U. R., Feltis J. T., Casadevall C., Zamarron A., Bernues M., Richard S., Lips C. J., Walther M. M., Tsui L. C., Geil L., Orcutt M. L., Stackhouse T., Zbar B. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat. Genet., 16: 68-73, 1997.[Medline]
17. Lee J. H., Han S. U., Cho H., Jennings B., Gerrard B., Dean M., Schmidt L., Zbar B., Vande Woude G. F. A novel germ line juxtamembrane Met mutation in human gastric cancer. Oncogene, 19: 4947-4953, 2000.[Medline]
18. Park W. S., Dong S. M., Kim S. Y., Na E. Y., Shin M. S., Pi J. H., Kim B. J., Bae J. H., Hong Y. K., Lee K. S., Lee S. H., Yoo N. J., Jang J. J., Pack S., Zhuang Z., Schmidt L., Zbar B., Lee J. Y. Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas. Cancer Res., 59: 307-310, 1999.[Abstract/Free Full Text]
19. Di Renzo M. F., Olivero M., Giacomini A., Porte H., Chastre E., Mirossay L., Nordlinger B., Bretti S., Bottardi S., Giordano S. Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer. Clin. Cancer Res., 1: 147-154, 1995.[Abstract]
20. Di Renzo M. F., Olivero M., Martone T., Maffe A., Maggiora P., Stefani A. D., Valente G., Giordano S., Cortesina G., Comoglio P. M. Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas. Oncogene, 19: 1547-1555, 2000.[Medline]
21. Bellusci S., Moens G., Gaudino G., Comoglio P., Nakamura T., Thiery J. P., Jouanneau J. Creation of an hepatocyte growth factor/scatter factor autocrine loop in carcinoma cells induces invasive properties associated with increased tumorigenicity. Oncogene, 9: 1091-1099, 1994.[Medline]
22. Jeffers M., Rong S., Anver M., Vande Woude G. F. Autocrine hepatocyte growth factor/scatter factor-Met signaling induces transformation and the invasive/metastastic phenotype in C127 cells. Oncogene, 13: 853-856, 1996.[Medline]
23. Rong S., Segal S., Anver M., Resau J. H., Vande Woude G. F. Invasiveness and metastasis of NIH 3T3 cells induced by Met-hepatocyte growth factor/scatter factor autocrine stimulation. Proc. Nat. Acad. Sci. USA, 91: 4731-4735, 1994.[Abstract/Free Full Text]
24. Jeffers M., Schmidt L., Nakaigawa N., Webb C. P., Weirich G., Kishida T., Zbar B., Vande Woude G. F. Activating mutations for the met tyrosine kinase receptor in human cancer. Proc. Nat. Acad. Sci. USA, 94: 11445-11450, 1997.[Abstract/Free Full Text]
25. Rong S., Bodescot M., Blair D., Dunn J., Nakamura T., Mizuno K., Park M., Chan A., Aaronson S., Vande Woude G. F. Tumorigenicity of the met proto-oncogene and the gene for hepatocyte growth factor. Mol. Cell. Biol., 12: 5152-5158, 1992.[Abstract/Free Full Text]
26. Takayama H., LaRochelle W. J., Sharp R., Otsuka T., Kriebel P., Anver M., Aaronson S. A., Merlino G. Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor. Proc. Nat. Acad. Sci. USA, 94: 701-706, 1997.[Abstract/Free Full Text]
27. Liang T. J., Reid A. E., Xavier R., Cardiff R. D., Wang T. C. Transgenic expression of tpr-met oncogene leads to development of mammary hyperplasia and tumors. J. Clin. Investig., 97: 2872-2877, 1996.[Medline]
28. Parr C., Hiscox S., Nakamura T., Matsumoto K., Jiang W. G. Nk4, a new HGF/SF variant, is an antagonist to the influence of HGF/SF on the motility and invasion of colon cancer cells. Int. J. Cancer, 85: 563-570, 2000.[Medline]
29. Michieli P., Basilico C., Pennacchietti S., Maffe A., Tamagnone L., Giordano S., Bardelli A., Comoglio P. M. Mutant Met-mediated transformation is ligand-dependent and can be inhibited by HGF antagonists. Oncogene, 18: 5221-5231, 1999.[Medline]
30. Atabey N., Gao Y., Yao Z. J., Breckenridge D., Soon L., Soriano J. V., Burke T. R., Jr., Bottaro D. P. Potent blockade of hepatocyte growth factor-stimulated cell motility, matrix invasion and branching morphogenesis by antagonists of Grb2 Src homology 2 domain interactions. J. Biol. Chem., 276: 14308-14314, 2001.[Abstract/Free Full Text]
31. Abounader R., Ranganathan S., Lal B., Fielding K., Book A., Dietz H., Burger P., Laterra J. Reversion of human glioblastoma malignancy by U1 small nuclear RNA/ribozyme targeting of scatter factor/hepatocyte growth factor and c-met expression. J. Natl. Cancer Inst., 91: 1548-1556, 1999.[Abstract/Free Full Text]
32. Morotti A., Mila S., Accornero P., Tagliabue E., Ponzetto C. K252a inhibits the oncogenic properties of Met, the HGF receptor. Oncogene, 21: 4885-4893, 2002.[Medline]
33. Rong S., Oskarsson M., Faletto D., Tsarfaty I., Resau J. H., Nakamura T., Rosen E., Hopkins R. F., 3rd, Vande Woude G. F. Tumorigenesis induced by coexpression of human hepatocyte growth factor and the human met protooncogene leads to high levels of expression of the ligand and receptor. Cell Growth Differ., 4: 563-569, 1993.[Abstract]
34. Blake R. A., Broome M. A., Liu X., Wu J., Gishizky M., Sun L., Courtneidge S. A. SU6656, a selective src family kinase inhibitor, used to probe growth factor signaling. Mol. Cell Biol., 20: 9019-9027, 2000.
35. Christensen J. G., Schreck R. E., Chan E., Wang X., Yang C., Liu L., Cui J., Sun L., Wei J., Cherrington J. M., Mendel D. B. High levels of HER-2 expression alter the ability of epidermal growth factor receptor (EGFR) family tyrosine kinase inhibitors to inhibit EGFR phosphorylation in vivo. Clin. Cancer Res., 7: 4230-4238, 2001.[Abstract/Free Full Text]
36. Stoker M., Gherardi E., Perryman M., Gray J. Scatter factor is a fibroblast-derived modulator of epithelial cell mobility. Nature (Lond.), 327: 239-242, 1987.[Medline]
37. Weidner K. M., Sachs M., Birchmeier W. The Met receptor tyrosine kinase transduces motility, proliferation, and morphogenic signals of scatter factor/hepatocyte growth factor in epithelial cells. J. Cell Biol., 121: 145-154, 1993.[Abstract/Free Full Text]
38. Nakaigawa N., Weirich G., Schmidt L., Zbar B. Tumorigenesis mediated by MET mutant M1268T is inhibited by dominant-negative Src. Oncogene, 19: 2996-3002, 2000.[Medline]
39. Liu Z. X., Yu C. F., Nickel C., Thomas S., Cantley L. G. Hepatocyte growth factor induces ERK-dependent paxillin phosphorylation and regulates paxillin-focal adhesion kinase association. J. Biol. Chem., 277: 10452-10458, 2002.[Abstract/Free Full Text]
40. Maulik G., Shrikhande A., Kijima T., Ma P. C., Morrison P. T., Salgia R. Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition. Cytokine Growth Factor Rev., 13: 41-59, 2002.[Medline]
41. Boccaccio C., Ando M., Tamagnone L., Bardelli A., Michieli P., Battistini C., Comoglio P. M. Induction of epithelial tubules by growth factor HGF depends on the STAT pathway. Nature (Lond.), 391: 285-288, 1998.[Medline]
42. Sachs M., Weidner K. M., Brinkmann V., Walther I., Obermeier A., Ullrich A., Birchmeier W. Motogenic and morphogenic activity of epithelial receptor tyrosine kinases. J. Cell Biol., 133: 1095-1107, 1996.[Abstract/Free Full Text]
43. Weidner K. M., Di Cesare S., Sachs M., Brinkmann V., Behrens J., Birchmeier W. Interaction between Gab1 and the c-Met receptor tyrosine kinase is responsible for epithelial morphogenesis. Nature (Lond.), 384: 173-176, 1996.[Medline]
44. Khwaja A., Lehmann K., Marte B. M., Downward J. Phosphoinositide 3-kinase induces scattering and tubulogenesis in epithelial cells through a novel pathway. J. Biol. Chem., 273: 18793-18801, 1998.[Abstract/Free Full Text]
45. Tanimura S., Nomura K., Ozaki K., Tsujimoto M., Kondo T., Kohno M. Prolonged nuclear retention of activated extracellular signal-regulated kinase 1/2 is required for hepatocyte growth factor-induced cell motility. J. Biol. Chem., 277: 28256-28264, 2002.[Abstract/Free Full Text]
46. Karihaloo A., O’Rourke D. A., Nickel C., Spokes K., Cantley L. G. Differential MAPK pathways utilized for HGF- and EGF-dependent renal epithelial morphogenesis. J. Biol. Chem., 276: 9166-9173, 2001.[Abstract/Free Full Text]
47. Potempa S., Ridley A. J. Activation of both MAP kinase and phosphatidylinositide 3-kinase by Ras is required for hepatocyte growth factor/scatter factor-induced adherens junction disassembly. Mol. Biol. Cell, 9: 2185-2200, 1998.[Abstract/Free Full Text]
48. Royal I., Fournier T. M., Park M. Differential requirement of Grb2 and PI3-kinase in HGF/SF-induced cell motility and tubulogenesis. J. Cell. Physiol., 173: 196-201, 1997.[Medline]
49. Xiao G. H., Jeffers M., Bellacosa A., Mitsuuchi Y., Vande Woude G. F., Testa J. R. Anti-apoptotic signaling by hepatocyte growth factor/Met via the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways. Proc. Nat. Acad. Sci. USA, 98: 247-252, 2001.[Abstract/Free Full Text]
50. Day R. M., Cioce V., Breckenridge D., Castagnino P., Bottaro D. P. Differential signaling by alternative HGF isoforms through c-Met: activation of both MAP kinase and PI 3-kinase pathways is insufficient for mitogenesis. Oncogene, 18: 3399-3406, 1999.[Medline]
51. Gual P., Giordano S., Williams T. A., Rocchi S., Van Obberghen E., Comoglio P. M. Sustained recruitment of phospholipase C- to Gab1 is required for HGF-induced branching tubulogenesis. Oncogene, 19: 1509-1518, 2000.[Medline]

This article has been cited by other articles:

				A. Bertotti, M. F. Burbridge, S. Gastaldi, F. Galimi, D. Torti, E. Medico, S. Giordano, S. Corso, G. Rolland-Valognes, B. P. Lockhart, et al. Only a Subset of Met-Activated Pathways Are Required to Sustain Oncogene Addiction Sci. Signal., December 8, 2009; 2(100): ra80 - ra80. [Abstract] [Full Text] [PDF]

				S. G. Buchanan, J. Hendle, P. S. Lee, C. R. Smith, P.-Y. Bounaud, K. A. Jessen, C. M. Tang, N. H. Huser, J. D. Felce, K. J. Froning, et al. SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo Mol. Cancer Ther., December 1, 2009; 8(12): 3181 - 3190. [Abstract] [Full Text] [PDF]

				W. Wang, Q. Li, T. Yamada, K. Matsumoto, I. Matsumoto, M. Oda, G. Watanabe, Y. Kayano, Y. Nishioka, S. Sone, et al. Crosstalk to Stromal Fibroblasts Induces Resistance of Lung Cancer to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Clin. Cancer Res., November 1, 2009; 15(21): 6630 - 6638. [Abstract] [Full Text] [PDF]

				B. Lal, C. R. Goodwin, Y. Sang, C. A. Foss, K. Cornet, S. Muzamil, M. G. Pomper, J. Kim, and J. Laterra EGFRvIII and c-Met pathway inhibitors synergize against PTEN-null/EGFRvIII+ glioblastoma xenografts Mol. Cancer Ther., July 1, 2009; 8(7): 1751 - 1760. [Abstract] [Full Text] [PDF]

				L. M. Knowles, L. P. Stabile, A. M. Egloff, M. E. Rothstein, S. M. Thomas, C. T. Gubish, E. C. Lerner, R. R. Seethala, S. Suzuki, K. M. Quesnelle, et al. HGF and c-Met Participate in Paracrine Tumorigenic Pathways in Head and Neck Squamous Cell Cancer Clin. Cancer Res., June 1, 2009; 15(11): 3740 - 3750. [Abstract] [Full Text] [PDF]

				A. Coxon, K. Rex, S. Meyer, J. Sun, J. Sun, Q. Chen, R. Radinsky, R. Kendall, and T. L. Burgess Soluble c-Met receptors inhibit phosphorylation of c-Met and growth of hepatocyte growth factor: c-Met-dependent tumors in animal models Mol. Cancer Ther., May 1, 2009; 8(5): 1119 - 1125. [Abstract] [Full Text] [PDF]

				G. Bonuccelli, M. C. Casimiro, F. Sotgia, C. Wang, M. Liu, S. Katiyar, J. Zhou, E. Dew, F. Capozza, K. M. Daumer, et al. Caveolin-1 (P132L), a Common Breast Cancer Mutation, Confers Mammary Cell Invasiveness and Defines a Novel Stem Cell/Metastasis-Associated Gene Signature Am. J. Pathol., May 1, 2009; 174(5): 1650 - 1662. [Abstract] [Full Text] [PDF]

				N. Smotrov, A. Mathur, I. Kariv, C. M. Moxham, and N. Bays Development of a Cell-Based Assay for Measurement of c-Met Phosphorylation Using AlphaScreenTM Technology and High-Content Imaging Analysis J Biomol Screen, April 1, 2009; 14(4): 404 - 411. [Abstract] [PDF]

				Y. Li, F. Guessous, C. DiPierro, Y. Zhang, T. Mudrick, L. Fuller, E. Johnson, L. Marcinkiewicz, M. Engelhardt, B. Kefas, et al. Interactions between PTEN and the c-Met pathway in glioblastoma and implications for therapy Mol. Cancer Ther., February 1, 2009; 8(2): 376 - 385. [Abstract] [Full Text] [PDF]

				P. N. Kongkham, P. A. Northcott, Y. S. Ra, Y. Nakahara, T. G. Mainprize, S. E. Croul, C. A. Smith, M. D. Taylor, and J. T. Rutka An Epigenetic Genome-Wide Screen Identifies SPINT2 as a Novel Tumor Suppressor Gene in Pediatric Medulloblastoma Cancer Res., December 1, 2008; 68(23): 9945 - 9953. [Abstract] [Full Text] [PDF]

				P. Giacobini, A. Messina, F. Morello, N. Ferraris, S. Corso, J. Penachioni, S. Giordano, L. Tamagnone, and A. Fasolo Semaphorin 4D regulates gonadotropin hormone-releasing hormone-1 neuronal migration through PlexinB1-Met complex J. Cell Biol., November 3, 2008; 183(3): 555 - 566. [Abstract] [Full Text] [PDF]

				T. Bachleitner-Hofmann, M. Y. Sun, C.-T. Chen, L. Tang, L. Song, Z. Zeng, M. Shah, J. G. Christensen, N. Rosen, D. B. Solit, et al. HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells Mol. Cancer Ther., November 1, 2008; 7(11): 3499 - 3508. [Abstract] [Full Text] [PDF]

				A. Korostylev, T. Worzfeld, S. Deng, R. H. Friedel, J. M. Swiercz, P. Vodrazka, V. Maier, A. Hirschberg, Y. Ohoka, S. Inagaki, et al. A functional role for semaphorin 4D/plexin B1 interactions in epithelial branching morphogenesis during organogenesis Development, October 15, 2008; 135(20): 3333 - 3343. [Abstract] [Full Text] [PDF]

				M. J. Binning, T. Niazi, C. A. Pedone, B. Lal, C. G. Eberhart, K. J. Kim, J. Laterra, and D. W. Fults Hepatocyte Growth Factor and Sonic Hedgehog Expression in Cerebellar Neural Progenitor Cells Costimulate Medulloblastoma Initiation and Growth Cancer Res., October 1, 2008; 68(19): 7838 - 7845. [Abstract] [Full Text] [PDF]

				G. K.Y. Chan, B. A. Lutterbach, B.-S. Pan, I. Kariv, and A. A. Szewczak High-Throughput Analysis of HGF-Stimulated Cell Scattering J Biomol Screen, October 1, 2008; 13(9): 847 - 854. [Abstract] [PDF]

				L. Toschi and P. A. Janne Single-Agent and Combination Therapeutic Strategies to Inhibit Hepatocyte Growth Factor/MET Signaling in Cancer Clin. Cancer Res., October 1, 2008; 14(19): 5941 - 5946. [Abstract] [Full Text] [PDF]

				C. Basilico, A. Arnesano, M. Galluzzo, P. M. Comoglio, and P. Michieli A High Affinity Hepatocyte Growth Factor-binding Site in the Immunoglobulin-like Region of Met J. Biol. Chem., July 25, 2008; 283(30): 21267 - 21277. [Abstract] [Full Text] [PDF]

				Z. Tiran, A. Oren, C. Hermesh, G. Rotman, Z. Levine, H. Amitai, T. Handelsman, M. Beiman, A. Chen, D. Landesman-Milo, et al. A Novel Recombinant Soluble Splice Variant of Met Is a Potent Antagonist of the Hepatocyte Growth Factor/Scatter Factor-Met Pathway Clin. Cancer Res., July 15, 2008; 14(14): 4612 - 4621. [Abstract] [Full Text] [PDF]

				J. R. Sierra, S. Corso, L. Caione, V. Cepero, P. Conrotto, A. Cignetti, W. Piacibello, A. Kumanogoh, H. Kikutani, P. M. Comoglio, et al. Tumor angiogenesis and progression are enhanced by Sema4D produced by tumor-associated macrophages J. Exp. Med., July 7, 2008; 205(7): 1673 - 1685. [Abstract] [Full Text] [PDF]

				B. Peruzzi and D. P Bottaro Targeting the c-Met Signaling Pathway in Cancer Am. Assoc. Cancer Res. Educ. Book, April 12, 2008; 2008(1): 61 - 68. [Abstract] [Full Text] [PDF]

				Y. Yang, M. Wislez, N. Fujimoto, L. Prudkin, J. G. Izzo, F. Uno, L. Ji, A. E. Hanna, R. R. Langley, D. Liu, et al. A selective small molecule inhibitor of c-Met, PHA-665752, reverses lung premalignancy induced by mutant K-ras Mol. Cancer Ther., April 1, 2008; 7(4): 952 - 960. [Abstract] [Full Text] [PDF]

				P. Accornero, G. Lattanzio, T. Mangano, R. Chiarle, R. Taulli, F. Bersani, P. E. Forni, S. Miretti, C. Scuoppo, W. Dastru, et al. An In vivo Model of Met-Driven Lymphoma as a Tool to Explore the Therapeutic Potential of Met Inhibitors Clin. Cancer Res., April 1, 2008; 14(7): 2220 - 2226. [Abstract] [Full Text] [PDF]

				Z. Yablonka-Reuveni, K. Day, A. Vine, and G. Shefer Defining the transcriptional signature of skeletal muscle stem cells J Anim Sci, April 1, 2008; 86(14_suppl): E207 - E216. [Abstract] [Full Text] [PDF]

				S. F. Bellon, P. Kaplan-Lefko, Y. Yang, Y. Zhang, J. Moriguchi, K. Rex, C. W. Johnson, P. E. Rose, A. M. Long, A. B. O'Connor, et al. c-Met Inhibitors with Novel Binding Mode Show Activity against Several Hereditary Papillary Renal Cell Carcinoma-related Mutations J. Biol. Chem., February 1, 2008; 283(5): 2675 - 2683. [Abstract] [Full Text] [PDF]

				T. E. Reznik, Y. Sang, Y. Ma, R. Abounader, E. M. Rosen, S. Xia, and J. Laterra Transcription-Dependent Epidermal Growth Factor Receptor Activation by Hepatocyte Growth Factor Mol. Cancer Res., January 1, 2008; 6(1): 139 - 150. [Abstract] [Full Text] [PDF]

				J. G. Christensen, H. Y. Zou, M. E. Arango, Q. Li, J. H. Lee, S. R. McDonnell, S. Yamazaki, G. R. Alton, B. Mroczkowski, and G. Los Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma Mol. Cancer Ther., December 1, 2007; 6(12): 3314 - 3322. [Abstract] [Full Text] [PDF]

				H.-L. Lin, S.-H. Chiou, C.-W. Wu, W.-B. Lin, L.-H. Chen, Y.-P. Yang, M.-L. Tsai, Y.-H. Uen, J.-P. Liou, and C.-W. Chi Combretastatin A4-Induced Differential Cytotoxicity and Reduced Metastatic Ability by Inhibition of AKT Function in Human Gastric Cancer Cells J. Pharmacol. Exp. Ther., October 1, 2007; 323(1): 365 - 373. [Abstract] [Full Text] [PDF]

				W. D. Tolbert, J. Daugherty, C. Gao, Q. Xie, C. Miranti, E. Gherardi, G. Vande Woude, and H. E. Xu A mechanistic basis for converting a receptor tyrosine kinase agonist to an antagonist PNAS, September 11, 2007; 104(37): 14592 - 14597. [Abstract] [Full Text] [PDF]

				J. M. Siegfried, C. T. Gubish, M. E. Rothstein, P. E. Q. de Oliveira, and L. P. Stabile Signaling Pathways Involved in Cyclooxygenase-2 Induction by Hepatocyte Growth Factor in Non Small-Cell Lung Cancer Mol. Pharmacol., September 1, 2007; 72(3): 769 - 779. [Abstract] [Full Text] [PDF]

				P. H. Huang, A. Mukasa, R. Bonavia, R. A. Flynn, Z. E. Brewer, W. K. Cavenee, F. B. Furnari, and F. M. White Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma PNAS, July 31, 2007; 104(31): 12867 - 12872. [Abstract] [Full Text] [PDF]

				S. Arena, A. Pisacane, M. Mazzone, P. M. Comoglio, and A. Bardelli Genetic targeting of the kinase activity of the Met receptor in cancer cells PNAS, July 3, 2007; 104(27): 11412 - 11417. [Abstract] [Full Text] [PDF]

				J. A. Engelman, K. Zejnullahu, T. Mitsudomi, Y. Song, C. Hyland, J. O. Park, N. Lindeman, C.-M. Gale, X. Zhao, J. Christensen, et al. MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling Science, May 18, 2007; 316(5827): 1039 - 1043. [Abstract] [Full Text] [PDF]

				H. Y. Zou, Q. Li, J. H. Lee, M. E. Arango, S. R. McDonnell, S. Yamazaki, T. B. Koudriakova, G. Alton, J. J. Cui, P.-P. Kung, et al. An Orally Available Small-Molecule Inhibitor of c-Met, PF-2341066, Exhibits Cytoreductive Antitumor Efficacy through Antiproliferative and Antiangiogenic Mechanisms Cancer Res., May 1, 2007; 67(9): 4408 - 4417. [Abstract] [Full Text] [PDF]

				N. Puri, A. Khramtsov, S. Ahmed, V. Nallasura, J. T. Hetzel, R. Jagadeeswaran, G. Karczmar, and R. Salgia A Selective Small Molecule Inhibitor of c-Met, PHA665752, Inhibits Tumorigenicity and Angiogenesis in Mouse Lung Cancer Xenografts Cancer Res., April 15, 2007; 67(8): 3529 - 3534. [Abstract] [Full Text] [PDF]

				P. Corsino, B. Davis, M. Law, A. Chytil, E. Forrester, P. Norgaard, N. Teoh, and B. Law Tumors Initiated by Constitutive Cdk2 Activation Exhibit Transforming Growth Factor {beta} Resistance and Acquire Paracrine Mitogenic Stimulation during Progression Cancer Res., April 1, 2007; 67(7): 3135 - 3144. [Abstract] [Full Text] [PDF]

				T. D. Francone, R. G. Landmann, C.-T. Chen, M. Y. Sun, E. J. Kuntz, Z. Zeng, R. P. Dematteo, P. B. Paty, and M. R. Weiser Novel xenograft model expressing human hepatocyte growth factor shows ligand-dependent growth of c-Met-expressing tumors Mol. Cancer Ther., April 1, 2007; 6(4): 1460 - 1466. [Abstract] [Full Text] [PDF]

				T. Standal, N. Abildgaard, U.-M. Fagerli, B. Stordal, O. Hjertner, M. Borset, and A. Sundan HGF inhibits BMP-induced osteoblastogenesis: possible implications for the bone disease of multiple myeloma Blood, April 1, 2007; 109(7): 3024 - 3030. [Abstract] [Full Text] [PDF]

				Z. Yu, P. M. Weinberger, C. Sasaki, B. L. Egleston, W. F. Speier IV, B. Haffty, D. Kowalski, R. Camp, D. Rimm, E. Vairaktaris, et al. Phosphorylation of Akt (Ser473) Predicts Poor Clinical Outcome in Oropharyngeal Squamous Cell Cancer Cancer Epidemiol. Biomarkers Prev., March 1, 2007; 16(3): 553 - 558. [Abstract] [Full Text] [PDF]

				M. Tsuda, I. J. Davis, P. Argani, N. Shukla, G. G. McGill, M. Nagai, T. Saito, M. Lae, D. E. Fisher, and M. Ladanyi TFE3 Fusions Activate MET Signaling by Transcriptional Up-regulation, Defining Another Class of Tumors as Candidates for Therapeutic MET Inhibition Cancer Res., February 1, 2007; 67(3): 919 - 929. [Abstract] [Full Text] [PDF]

				W. M. Linehan, P. A. Pinto, R. Srinivasan, M. Merino, P. Choyke, L. Choyke, J. Coleman, J. Toro, G. Glenn, C. Vocke, et al. Identification of the Genes for Kidney Cancer: Opportunity for Disease-Specific Targeted Therapeutics Clin. Cancer Res., January 15, 2007; 13(2): 671s - 679s. [Abstract] [Full Text] [PDF]

				O. Iliopoulos Molecular Biology of Renal Cell Cancer and the Identification of Therapeutic Targets J. Clin. Oncol., December 10, 2006; 24(35): 5593 - 5600. [Abstract] [Full Text] [PDF]

				I. Mukhopadhyay, E. A. Sausville, J. H. Doroshow, and K. K. Roy Molecular Mechanism of Adaphostin-mediated G1 Arrest in Prostate Cancer (PC-3) Cells: SIGNALING EVENTS MEDIATED BY HEPATOCYTE GROWTH FACTOR RECEPTOR, c-Met, AND p38 MAPK PATHWAYS J. Biol. Chem., December 8, 2006; 281(49): 37330 - 37344. [Abstract] [Full Text] [PDF]

				G. Cassinelli, C. Lanzi, G. Petrangolini, M. Tortoreto, G. Pratesi, G. Cuccuru, D. Laccabue, R. Supino, S. Belluco, E. Favini, et al. Inhibition of c-Met and prevention of spontaneous metastatic spreading by the 2-indolinone RPI-1. Mol. Cancer Ther., September 1, 2006; 5(9): 2388 - 2397. [Abstract] [Full Text] [PDF]

				M. Mazzone and P. M. Comoglio The Met pathway: master switch and drug target in cancer progression FASEB J, August 1, 2006; 20(10): 1611 - 1621. [Abstract] [Full Text] [PDF]

				L. P. Stabile, J. S. Lyker, S. R. Land, S. Dacic, B. A. Zamboni, and J. M. Siegfried Transgenic mice overexpressing hepatocyte growth factor in the airways show increased susceptibility to lung cancer Carcinogenesis, August 1, 2006; 27(8): 1547 - 1555. [Abstract] [Full Text] [PDF]

				B. Peruzzi and D. P. Bottaro Targeting the c-Met Signaling Pathway in Cancer. Clin. Cancer Res., June 15, 2006; 12(12): 3657 - 3660. [Abstract] [Full Text] [PDF]

				A. Petrelli, P. Circosta, L. Granziero, M. Mazzone, A. Pisacane, S. Fenoglio, P. M. Comoglio, and S. Giordano Ab-induced ectodomain shedding mediates hepatocyte growth factor receptor down-regulation and hampers biological activity PNAS, March 28, 2006; 103(13): 5090 - 5095. [Abstract] [Full Text] [PDF]

				J. S. Melnick, J. Janes, S. Kim, J. Y. Chang, D. G. Sipes, D. Gunderson, L. Jarnes, J. T. Matzen, M. E. Garcia, T. L. Hood, et al. An efficient rapid system for profiling the cellular activities of molecular libraries PNAS, February 28, 2006; 103(9): 3153 - 3158. [Abstract] [Full Text] [PDF]

				G. A. Smolen, R. Sordella, B. Muir, G. Mohapatra, A. Barmettler, H. Archibald, W. J. Kim, R. A. Okimoto, D. W. Bell, D. C. Sgroi, et al. Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752 PNAS, February 14, 2006; 103(7): 2316 - 2321. [Abstract] [Full Text] [PDF]

				V. Sangwan, G. N. Paliouras, A. Cheng, N. Dube, M. L. Tremblay, and M. Park Protein-tyrosine Phosphatase 1B Deficiency Protects against Fas-induced Hepatic Failure J. Biol. Chem., January 6, 2006; 281(1): 221 - 228. [Abstract] [Full Text] [PDF]

				G. Rossi, A. Cavazza, A. Marchioni, L. Longo, M. Migaldi, G. Sartori, N. Bigiani, L. Schirosi, C. Casali, U. Morandi, et al. Role of Chemotherapy and the Receptor Tyrosine Kinases KIT, PDGFR{alpha}, PDGFR{beta}, and Met in Large-Cell Neuroendocrine Carcinoma of the Lung J. Clin. Oncol., December 1, 2005; 23(34): 8774 - 8785. [Abstract] [Full Text] [PDF]

				T. Mukohara, G. Civiello, I. J. Davis, M. L. Taffaro, J. Christensen, D. E. Fisher, B. E. Johnson, and P. A. Janne Inhibition of the Met Receptor in Mesothelioma Clin. Cancer Res., November 15, 2005; 11(22): 8122 - 8130. [Abstract] [Full Text] [PDF]

				R. Abounader and J. Laterra Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis Neuro Oncology, October 1, 2005; 7(4): 436 - 451. [Abstract] [PDF]

				T.-L. Cheng, M.-Y. Chang, S.-Y. Huang, C.-C. Sheu, E.-L. Kao, Y.-J. Cheng, and I.-W. Chong Overexpression of Circulating c-Met Messenger RNA Is Significantly Correlated With Nodal Stage and Early Recurrence in Non-Small Cell Lung Cancer Chest, September 1, 2005; 128(3): 1453 - 1460. [Abstract] [Full Text] [PDF]

				M. R. D'Andrea, J. M. Mei, R. W. Tuman, R. A. Galemmo, and D. L. Johnson Validation of in vivo pharmacodynamic activity of a novel PDGF receptor tyrosine kinase inhibitor using immunohistochemistry and quantitative image analysis Mol. Cancer Ther., August 1, 2005; 4(8): 1198 - 1204. [Abstract] [Full Text] [PDF]

				B. Lal, S. Xia, R. Abounader, and J. Laterra Targeting the c-Met Pathway Potentiates Glioblastoma Responses to {gamma}-Radiation Clin. Cancer Res., June 15, 2005; 11(12): 4479 - 4486. [Abstract] [Full Text] [PDF]

				M. R. Morris, D. Gentle, M. Abdulrahman, E. N. Maina, K. Gupta, R. E. Banks, M. S. Wiesener, T. Kishida, M. Yao, B. Teh, et al. Tumor Suppressor Activity and Epigenetic Inactivation of Hepatocyte Growth Factor Activator Inhibitor Type 2/SPINT2 in Papillary and Clear Cell Renal Cell Carcinoma Cancer Res., June 1, 2005; 65(11): 4598 - 4606. [Abstract] [Full Text] [PDF]

				P. C. Ma, E. Schaefer, J. G. Christensen, and R. Salgia A Selective Small Molecule c-MET Inhibitor, PHA665752, Cooperates with Rapamycin Clin. Cancer Res., March 15, 2005; 11(6): 2312 - 2319. [Abstract] [Full Text] [PDF]

				N. Shinomiya, C. F. Gao, Q. Xie, M. Gustafson, D. J. Waters, Y.-W. Zhang, and G. F. Vande Woude RNA Interference Reveals that Ligand-Independent Met Activity Is Required for Tumor Cell Signaling and Survival Cancer Res., November 1, 2004; 64(21): 7962 - 7970. [Abstract] [Full Text] [PDF]

				H. Hov, R. U. Holt, T. B. Ro, U.-M. Fagerli, H. Hjorth-Hansen, V. Baykov, J. G. Christensen, A. Waage, A. Sundan, and M. Borset A Selective c-Met Inhibitor Blocks an Autocrine Hepatocyte Growth Factor Growth Loop in ANBL-6 Cells and Prevents Migration and Adhesion of Myeloma Cells Clin. Cancer Res., October 1, 2004; 10(19): 6686 - 6694. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Christensen, J. G. Articles by Mendel, D. B. Search for Related Content PubMed PubMed Citation Articles by Christensen, J. G. Articles by Mendel, D. B.